Fortress Biotech vs Roivant Sciences
FBIO and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FBIO and ROIV compare
Roivant Sciences is the larger company, worth 413 times as much as Fortress Biotech ($28.6B against $69.1M).
Roivant Sciences grew revenue faster over the last twelve months (102% versus 12.3% for Fortress Biotech).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 143% compared with −838% at Roivant Sciences.
Fortress Biotech scores higher on the StockData Score (9 against 8 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FBIO | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $69.1M | $28.6B |
| Share price | $1.88 | $39.53 |
| Change, 1 year | −28.2% | 85.4% |
| Change, 5 years | −95.9% | 394% |
| Beta (5Y) | 1.37 | 0.85 |
| Employees | 78 | 721 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 695× |
| P/B | 0.4× (better) | 7.1× |
| FCF yield | – | −0.12% |
| Growth | ||
| Revenue growth (TTM) | 12.3% | 102% (better) |
| Revenue growth, 5Y average | 6.8% (better) | −19.1% |
| Net income growth (TTM) | 2411% | – |
| Profitability | ||
| Gross margin | 66.2% | – |
| Operating margin | −42.5% (better) | −1358% |
| Net margin | 143% (better) | −838% |
| FCF margin | – | −81.2% |
| Return on equity | 92.8% (better) | −8.2% |
| Return on invested capital | −132% | – |
| Financial health | ||
| Debt / equity | 0.11 (better) | 0.00 |
| Interest coverage | −3.2× | – |
| Current ratio | 2.93 | 15.56 (better) |
| Altman Z-score | −2.25 | 45.37 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.9% | 78.1% |
| Held by insiders | 31.6% | 13.9% |
| Insider net buying, 12 months | – | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.3% |
Go deeper
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.